Threads and yarns: weaving the tapestry of comorbidity.
作者信息
Starfield Barbara
出版信息
Ann Fam Med. 2006 Mar-Apr;4(2):101-3. doi: 10.1370/afm.524.
Abstract
摘要
相似文献
1
Threads and yarns: weaving the tapestry of comorbidity.
Ann Fam Med. 2006 Mar-Apr;4(2):101-3. doi: 10.1370/afm.524.
2
"Eligibility" is key word in Fistula First Breakthrough Initiative in determining fistula use.
Nephrol News Issues. 2006 Aug;20(9):39-40.
3
Standards of proof, standards of practice, and proof of standards: a tale of two trials.
J Clin Oncol. 2005 Apr 20;23(12):2583-5. doi: 10.1200/JCO.2005.11.910. Epub 2005 Feb 14.
4
Randomized controlled trials: do they have external validity for patients with multiple comorbidities?
Ann Fam Med. 2006 Mar-Apr;4(2):104-8. doi: 10.1370/afm.516.
5
Acronyms and anachronisms.
Am J Sports Med. 2008 Nov;36(11):2081-2. doi: 10.1177/0363546508326370.
6
Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.
J Psychopharmacol. 2004 Sep;18(3):293-335. doi: 10.1177/026988110401800321.
7
Clinical practice guidelines on trial.
CMAJ. 1997 Jun 15;156(12):1725-7.
8
Walk a mile in my shoes.
Anesth Analg. 2010 Aug;111(2):264-5. doi: 10.1213/ANE.0b013e3181cd6e76.
9
Walk a mile in whose shoes?
Anesth Analg. 2010 Aug;111(2):576-7; author reply 577. doi: 10.1213/ANE.0b013e3181e63976.
10
[What is the function of "practice guidelines"?].
Ann Dermatol Venereol. 1999 Mar;126(3):207-9.
引用本文的文献
1
Electronic Health Records: A Gateway to AI-Driven Multimorbidity Solutions-A Comprehensive Systematic Review.
J Clin Med. 2025 May 14;14(10):3434. doi: 10.3390/jcm14103434.
2
Multimorbidity patterns and trajectories in young and middle-aged adults: a large-scale population-based cohort study.
Front Public Health. 2024 May 16;12:1349723. doi: 10.3389/fpubh.2024.1349723. eCollection 2024.
3
Integrated Pleiotropic Gene Set Unveils Comorbidity Insights across Digestive Cancers and Other Diseases.
Genes (Basel). 2024 Apr 10;15(4):478. doi: 10.3390/genes15040478.
4
Assessing the properties of patient-specific treatment effect estimates from causal forest algorithms under essential heterogeneity.
BMC Med Res Methodol. 2024 Mar 13;24(1):66. doi: 10.1186/s12874-024-02187-5.
5
Impact of primary care usual provider type and provider interdependence on outcomes for patients with diabetes: a cohort study.
BMJ Open Qual. 2023 Jun;12(2). doi: 10.1136/bmjoq-2022-002229.
6
Assessing the ability of an instrumental variable causal forest algorithm to personalize treatment evidence using observational data: the case of early surgery for shoulder fracture.
BMC Med Res Methodol. 2022 Jul 11;22(1):190. doi: 10.1186/s12874-022-01663-0.
7
[Not Available].
Can Fam Physician. 2021 Apr;67(4):242-245. doi: 10.46747/cfp.6704242.
8
Implementing patient-centred integrated care for multiple chronic conditions: Evidence-informed framework.
Can Fam Physician. 2021 Apr;67(4):235-238. doi: 10.46747/cfp.6704235.
9
Socioeconomic Position, Multimorbidity and Mortality in a Population Cohort: The HUNT Study.
J Clin Med. 2020 Aug 26;9(9):2759. doi: 10.3390/jcm9092759.
10
Comparison of Primary Care Experience in Hospital-Based Practices and Community-Based Office Practices in Japan.
Ann Fam Med. 2020 Jan;18(1):24-29. doi: 10.1370/afm.2463.
本文引用的文献
1
Randomized controlled trials: do they have external validity for patients with multiple comorbidities?
Ann Fam Med. 2006 Mar-Apr;4(2):104-8. doi: 10.1370/afm.516.
2
Taking the pulse of health care systems: experiences of patients with health problems in six countries.
Health Aff (Millwood). 2005 Jul-Dec;Suppl Web Exclusives:W5-509-25. doi: 10.1377/hlthaff.w5.509.
3
Contribution of primary care to health systems and health.
Milbank Q. 2005;83(3):457-502. doi: 10.1111/j.1468-0009.2005.00409.x.
4
Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.
JAMA. 2005 Aug 10;294(6):716-24. doi: 10.1001/jama.294.6.716.
5
Prevalence of multimorbidity among adults seen in family practice.
Ann Fam Med. 2005 May-Jun;3(3):223-8. doi: 10.1370/afm.272.
6
Comorbidity and the use of primary care and specialist care in the elderly.
Ann Fam Med. 2005 May-Jun;3(3):215-22. doi: 10.1370/afm.307.
7
The effects of specialist supply on populations' health: assessing the evidence.
Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-97-W5-107. doi: 10.1377/hlthaff.w5.97.
8
Surrogate endpoints and FDA's accelerated approval process.
Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78. doi: 10.1377/hlthaff.24.1.67.
9
Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.
Lancet. 2005;365(9454):176-86. doi: 10.1016/S0140-6736(05)17709-5.
10
Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.
Milbank Q. 2004;82(4):661-87. doi: 10.1111/j.0887-378X.2004.00327.x.
Zotero 插件